Sorry, you need to enable JavaScript to visit this website.

This site is intended only for healthcare professionals resident in the United Kingdom


Haemophilia, affecting around 1 in 10 000 people1, is one of Pfizer’s rare disease focuses. Our portfolio includes treatments targeted at the genetic variants of haemophilia for prevention and treatment of serious bleeding.